Daphne Stewart, MD
Medical Oncology · Los Angeles, CANPI 1598879918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 27.1% of the total. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 17 payments — averaging $43.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$203
- Novartis$156
- Pfizer$119
- Tempus AI, Inc$111
- GSK$94
- Jazz Pharmaceuticals Inc.$23
- plus $41 from 3 others
Across 275 payments — averaging $14,385 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.8M
- AstraZeneca$306K
- Hoffmann-la Roche Limited$173K
- Incyte Corporation$172K
- Astrazeneca UK Limited$138K
- Genentech, Inc.$83K
- plus $307K from 7 others
What the payments were for
- Food & beverage$73598%
- Education$122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $203 |
| Novartis | 4 | $156 |
| Pfizer | 1 | $119 |
| Tempus AI, Inc | 1 | $111 |
| GSK | 4 | $94 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$747 in reported general payments places this provider in the 30th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 12 | $1,812 |
| Anastrozole | 63 | $1,348 |
| Letrozole | 29 | $455 |
| Tamoxifen Citrate | 12 | $148 |
| Gabapentin | 13 | $83 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.